ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!OTLK Company Profile and Key Details
Outlook Therapeutics, Inc.
OTLK Stock Price Chart
Stock Price Today
Outlook Therapeutics, Inc. (OTLK) stock declined over -5.33%, trading at $1.42 on NASDAQ, down from the previous close of $1.50. The stock opened at $1.56, fluctuating between $1.42 and $1.57 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Company Information
| Employees | 23 |
| Beta | 0.58 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | September |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Outlook Therapeutics, Inc. (NASDAQ: OTLK) stock price is $1.42 in the last trading session. During the trading session, OTLK stock reached the peak price of $1.57 while $1.42 was the lowest point it dropped to. The percentage change in OTLK stock occurred in the recent session was -5.33% while the dollar amount for the price change in OTLK stock was -$0.08.
The NASDAQ listed OTLK is part of Biotechnology industry that operates in the broader Healthcare sector. Outlook Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Rick Gregory
Director of Marketing & Communications
Mr. C. Russell Trenary III
Pres, Chief Executive Officer & Director
Mr. Lawrence A. Kenyon CPA
Executive Vice President, Chief Financial Officer, Treasurer, Company Sec. & Director
Mr. Terry Dagnon
Chief Operations Officer
Ms. Elizabeth A. Yamashita
Advisor
Ms. Alicia Tozier
Senior Vice President, Marketing & Market Access
Dr. Surendra Sharma M.D.
Senior Vice President of Medical Affairs
Mr. Jeffrey Evanson
Chief Commercial Officer
Mr. Ralph H. Thurman
Independent Executive Chairman
Mr. Joel Prieve
Senior Vice President of Commercial Operations
OTLK's closing price is 63.22% higher than its 52-week low of $0.87 where as its distance from 52-week high of $12.85 is -88.95%.
Number of OTLK employees currently stands at 23.
Official Website of OTLK is: https://www.outlooktherapeutics.com
OTLK could be contacted at phone 609 619 3990 and can also be accessed through its website. OTLK operates from Building F, Iselin, NJ 08852, United States.
OTLK stock volume for the day was 700.24K shares. The average number of OTLK shares traded daily for last 3 months was 962.1K.
The market value of OTLK currently stands at $45.46M with its latest stock price at $1.42 and 32.02M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com